Acts38 Boswelliagel

Boswellia Serrata Extract,, Acetyl Glucosamine , Centella Asiatica Extract, Sodium Hyaluronate


A-lot Biologics Inc
Human Otc Drug
NDC 82967-0001
Acts38 Boswelliagel also known as Boswellia Serrata Extract,, Acetyl Glucosamine , Centella Asiatica Extract, Sodium Hyaluronate is a human otc drug labeled by 'A-lot Biologics Inc'. National Drug Code (NDC) number for Acts38 Boswelliagel is 82967-0001. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Acts38 Boswelliagel drug includes Centella Asiatica - .01 g/100mL Hyaluronate Sodium - .01 g/100mL Indian Frankincense - 1.2 g/100mL N-acetylglucosamine - .1 g/100mL . The currest status of Acts38 Boswelliagel drug is Active.

Drug Information:

Drug NDC: 82967-0001
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Acts38 Boswelliagel
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Boswellia Serrata Extract,, Acetyl Glucosamine , Centella Asiatica Extract, Sodium Hyaluronate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: A-lot Biologics Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CENTELLA ASIATICA - .01 g/100mL
HYALURONATE SODIUM - .01 g/100mL
INDIAN FRANKINCENSE - 1.2 g/100mL
N-ACETYLGLUCOSAMINE - .1 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 07 Sep, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:A-Lot Biologics Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:8809844570036
UPC stands for Universal Product Code.
UNII:7M867G6T1U
YSE9PPT4TH
4PW41QCO2M
V956696549
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
82967-0001-130 mL in 1 TUBE (82967-0001-1)07 Sep, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Simply massage the act38 over painful areas for beneficial effects including: - pain relief for arthritic pain, neck and shoulder pain, back pain and more - decrease in joint swelling - improved blood supply to inflamed joints - increasing joint suppleness - powerful anti-inflammatory effects - relieves stiff and sore muscles

Product Elements:

Acts38 boswelliagel boswellia serrata extract,, acetyl glucosamine , centella asiatica extract, sodium hyaluronate n-acetylglucosamine n-acetylglucosamine hyaluronate sodium hyaluronic acid water indian frankincense indian frankincense centella asiatica centella asiatica

Indications and Usage:

Take an appropriate amount of the product and gently rub it on necessary areas such as knees, elbows, ankles, and wrists to spread it evenly.

Warnings:

1) if there are abnormal symptoms or side effects such as red spots, swelling, or itching in the area of use of cosmetics or direct sunlight after use, consult a specialist 2) refrain from using injured areas 3) precautions for storage and handling a) keep out of reach of children b) store away from direct sunlight

Dosage and Administration:

For external use only

Package Label Principal Display Panel:

Label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.